VELTIN
LOE ApproachingNDATOPICALGEL
Approved
Jul 2010
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
2/8 — Basic
VELTIN by Almirall is clindamycin: [see microbiology (). First approved in 2010.
Drug data last refreshed 1h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
VELTIN is a fixed-dose topical gel combining clindamycin (antibiotic) and tretinoin (retinoid) approved in 2010 for acne treatment. Clindamycin provides antimicrobial activity against acne-causing bacteria, while tretinoin decreases follicular cell cohesiveness and promotes epithelial turnover to prevent comedone formation. The combination addresses both inflammatory and comedonal acne through synergistic mechanisms.
LOE Approaching
As VELTIN approaches loss of exclusivity with moderate competitive pressure (30/100), the brand team is likely transitioning from peak-market strategies to value-based positioning and generic containment.
Mechanism of Action
Clindamycin: [See Microbiology ().] Tretinoin: Although the exact mode of action of tretinoin is unknown, current evidence suggests that topical tretinoin decreases cohesiveness of folliculare epithelial cells with decreased microcomedone formation. Additionally, tretinoin stimulates mitotic…
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
VELTIN offers limited career dynamism given its LOE-approaching status and lack of linked job postings; roles available are primarily defensive brand maintenance, managed markets access, and field reimbursement support. Career growth on this asset is constrained compared to early-lifecycle or high-growth portfolio brands.
Brand Manager
Worked on VELTIN at Almirall? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.